Shanghai Bio-heart Biological Technology (HKG:2185) said its subsidiary, Shanghai AngioCare Medical Technology, has completed the first commercial procedure of its Iberis multi-electrode renal artery radiofrequency ablation catheter system in Switzerland, according to a Thursday Hong Kong bourse filing.

Shares of the medical device company gained nearly 5% in Friday morning trade.

The procedure, conducted at University Hospital Basel, was completed without complications or adverse events, the company said.

The project was supported jointly by Biosensors International Group, a subsidiary of Blue Sail Medical (SHE:002382), under an existing partnership covering the EU, Asia-Pacific, and Latin America markets.